Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.

Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM.

Haemophilia. 2012 Mar;18(2):268-75. doi: 10.1111/j.1365-2516.2011.02692.x.

2.

Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.

Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM.

Haemophilia. 2012 Mar;18(2):276-83. doi: 10.1111/j.1365-2516.2011.02713.x.

3.

Costs and utilization of hemophilia A and B patients with and without inhibitors.

Armstrong EP, Malone DC, Krishnan S, Wessler MJ.

J Med Econ. 2014 Nov;17(11):798-802. doi: 10.3111/13696998.2014.953679.

PMID:
25111634
4.

Costs and utilization of treatment in patients with hemophilia.

Rocha P, Carvalho M, Lopes M, Araújo F.

BMC Health Serv Res. 2015 Oct 26;15:484. doi: 10.1186/s12913-015-1134-3.

5.

Hemophilia. Treatment of patients with inhibitors: cost issues.

Goudemand J.

Haemophilia. 1999 Nov;5(6):397-401.

PMID:
10583526
6.

Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.

Nerich V, Tissot E, Faradji A, Demesmay K, Bertrand MA, Lorenzini JL, Briquel ME, Pouzol P, Woronoff-Lemsi MC.

Pharm World Sci. 2008 Jun;30(3):287-92.

PMID:
18085428
7.

Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.

Majumdar S, Ostrenga A, Latzman RD, Payne C, Hunt Q, Morris A, Iyer R.

Haemophilia. 2011 Jul;17(4):717-8. doi: 10.1111/j.1365-2516.2010.02462.x. No abstract available.

PMID:
21323798
8.

Inhibitor economics.

Teitel J.

Semin Hematol. 2006 Apr;43(2 Suppl 4):S14-7. Review.

PMID:
16690371
9.

Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan.

Tu TC, Liou WS, Chou TY, Lin TK, Lee CF, Chen JD, Cham TM, Chung MI.

Yonsei Med J. 2013 Jan 1;54(1):71-80. doi: 10.3349/ymj.2013.54.1.71. Erratum in: Yonsei Med J. 2013 Mar 1;54(2):543.

10.

Healthcare resource utilization among haemophilia A patients in the United States.

Valentino LA, Pipe SW, Tarantino MD, Ye X, Xiong Y, Luo MP.

Haemophilia. 2012 May;18(3):332-8. doi: 10.1111/j.1365-2516.2011.02677.x.

PMID:
22044662
11.

Cost of care of haemophilia with inhibitors.

Di Minno MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A.

Haemophilia. 2010 Jan;16(1):e190-201. doi: 10.1111/j.1365-2516.2009.02100.x. Review.

PMID:
19845772
12.

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators..

Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302.

13.

Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.

Tencer T, Friedman HS, Li-McLeod J, Johnson K.

J Manag Care Pharm. 2007 Nov-Dec;13(9):790-8.

14.

Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.

Stieltjes N, Torchet MF, Misrahi L, Roussel-Robert V, Lambert T, Guérois C, Bertrand MA, Briquel ME, Borel-Derlon A, Dirat G.

Blood Coagul Fibrinolysis. 2009 Jan;20(1):4-11.

PMID:
20527720
15.

Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review.

Khleif AA, Rodriguez N, Brown D, Escobar MA.

Haemophilia. 2012 May;18(3):e95-e100. doi: 10.1111/j.1365-2516.2011.02649.x.

PMID:
21910793
16.

Haemophilia care in Europe: the ESCHQoL study.

Schramm W, Gringeri A, Ljung R, Berger K, Crispin A, Bullinger M, Giangrande PL, Von Mackensen S, Mantovani LG, Nemes L, Serban M; ESCHQOL Study Group..

Haemophilia. 2012 Sep;18(5):729-37. doi: 10.1111/j.1365-2516.2012.02847.x.

PMID:
22639833
17.

Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.

Ullman M, Hoots WK.

Haemophilia. 2006 Dec;12 Suppl 6:74-9; discussion 79-80.

PMID:
17123398
18.

The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.

Harper P, Brasser M, Moore L, Teague L, Pitcher L, Ockelford P.

N Z Med J. 2003 Aug 22;116(1180):U561.

PMID:
14581983
19.

Haemophilia treatment: where to from here? Have the risks increased?

Faed J.

N Z Med J. 2003 Aug 22;116(1180):U559. No abstract available.

PMID:
14581981
20.

The economic impact of factor VIII inhibitors in patients with haemophilia.

Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J.

Haemophilia. 2004 Jan;10(1):63-8.

PMID:
14962222
Items per page

Supplemental Content

Support Center